Olanzapine News and Research RSS Feed - Olanzapine News and Research

Olanzapine (trade names Zyprexa, Zyprexa Zydis, Zalasta, Zolafren, Olzapin, Rexapin or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.
Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Alkermes plc today announced the initiation of the second phase 2 study of ALKS 3831, a novel, oral, broad-spectrum antipsychotic medicine in development for schizophrenia. [More]
Mylan releases generic version of Zyprexa Zydis Tablets

Mylan releases generic version of Zyprexa Zydis Tablets

Mylan Inc. today announced that it has launched Olanzapine Orally Disintegrating Tablets (ODT), 5 mg, 10 mg, 15 mg and 20 mg, the generic version of Eli Lilly and Company's Zyprexa Zydis Tablets. [More]
Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc. [More]
Antipsychotic drugs for children with behavioral problems may put at risk for type 2 diabetes

Antipsychotic drugs for children with behavioral problems may put at risk for type 2 diabetes

Prescribing of "atypical" antipsychotic medications to children and young adults with behavioral problems or mood disorders may put them at unnecessary risk for type 2 diabetes, a Vanderbilt University Medical Center study shows. [More]
Alkermes reports positive results from phase 1 study of ALKS 3831 for treatment of schizophrenia

Alkermes reports positive results from phase 1 study of ALKS 3831 for treatment of schizophrenia

Alkermes plc today presented positive results from a phase 1 study of ALKS 3831, a novel drug candidate for the treatment of schizophrenia, in an oral session at the 53rd Annual New Clinical Drug Evaluation Unit Meeting in Hollywood, Fla. [More]
Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

In older adults, antipsychotic drugs are commonly prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications - schizophrenia and bipolar disorder. The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia, some of which carry FDA warnings on prescription information for these drugs. [More]
FDA accepts Sunovion’s two LATUDA sNDAs for review

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression). [More]
Adjunctive drugs hasten sedation in the emergency department

Adjunctive drugs hasten sedation in the emergency department

Adding intravenous droperidol or olanzapine to midazolam shortens the time to adequate sedation in acutely agitated patients in the emergency department, show findings from a randomized controlled trial. [More]
Antipsychotic use in pregnancy should be closely monitored

Antipsychotic use in pregnancy should be closely monitored

Use of any type of antipsychotic during pregnancy increases the risk for women developing gestational diabetes, show Swedish study results that also indicate a link between antipsychotics and a risk for giving birth to a small for gestational age infant. [More]
Gestational diabetes may be more likely with antipsychotic use

Gestational diabetes may be more likely with antipsychotic use

Women who take antipsychotic medication during pregnancy may be at an increased risk for developing gestational diabetes, report researchers. [More]
Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Teva Pharmaceutical Industries Ltd. announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax. [More]
Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA. [More]
Teva first quarter net revenues increase 25% to $5.1 billion

Teva first quarter net revenues increase 25% to $5.1 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended March 31, 2012. [More]
Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone). [More]
Mylan receives final FDA approval for generic Zyprexa ANDA

Mylan receives final FDA approval for generic Zyprexa ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Olanzapine Tablets USP, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg. [More]
Olanzapine improves survival in mouse model of anorexia nervosa

Olanzapine improves survival in mouse model of anorexia nervosa

Low doses of a commonly used atypical antipsychotic drug improved survival in a mouse model of anorexia nervosa, University of Chicago researchers report this month. The result offers promise for a common and occasionally fatal eating disorder that currently lacks approved drugs for treatment. [More]
Weight gain or loss may also depend on medicines taken

Weight gain or loss may also depend on medicines taken

Weight gain or loss may not always be caused by what you eat or how much you exercise. For some, it's the medicines you're taking. [More]
Dr. Reddy’s third quarter revenues increase 46% to $522 million

Dr. Reddy’s third quarter revenues increase 46% to $522 million

Dr. Reddy's Laboratories Ltd. today announced its unaudited consolidated financial results for the quarter ended December 31, 2011 under International Financial Reporting Standards. [More]
New report finds little evidence to support off-label use of atypical antipsychotics

New report finds little evidence to support off-label use of atypical antipsychotics

There is little evidence to support the use of atypical antipsychotic drugs for some treatments other than their officially approved purposes, even though many clinicians continue to commonly prescribe these drugs for so-called "off label" uses, according to a new report from the U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality. [More]
Benefits and harms vary among atypical antipsychotics for off-label use

Benefits and harms vary among atypical antipsychotics for off-label use

A review of previous studies suggests that even though atypical antipsychotic medications are commonly used for off-label conditions such as behavioral symptoms of dementia, anxiety, and obsessive-compulsive disorder, these medications are effective for only a few off-label conditions, and that the benefits and harms of these medications for these uses vary, according to an article in the September 28 issue of JAMA. [More]